Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 3, 2013, Pages 344-356

  Bayraktar, Ulas D ^a   Bashir, Qaiser ^a   Qazilbash, Muzaffar ^a   Champlin, Richard E ^a   Ciurea, Stefan O ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Conditioning regimens; Melphalan; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ARABINOSIDE; BENDAMUSTINE; BUSULFAN; CARMUSTINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOTEMUSTINE; GEMCITABINE; MELPHALAN; PREDNISONE; THALIDOMIDE; THIOTEPA; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMYLOIDOSIS; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL PROTOCOL; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG MEGADOSE; DRUG SUBSTITUTION; ENGRAFTMENT; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HODGKIN DISEASE; HUMAN; INCIDENCE; LUNG COMPLICATION; MAINTENANCE CHEMOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; NEUROLOGICAL COMPLICATION; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; SEPSIS; SURVIVAL RATE;

ADENINE NUCLEOTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; BORONIC ACIDS; GRAFT SURVIVAL; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; PYRAZINES; THALIDOMIDE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84873713032     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.08.011     Document Type: Review

References (167)

1. Bergel F., Stock J.A. Cytotoxic alpha amino acids and endopeptidase. Br Emp Cancer Comp Annu 1953, 31:6-21.
2. Sarosy G., Leyland-Jones B., Soochan P., Cheson B.D. The systemic administration of intravenous melphalan. J Clin Oncol 1988, 6:1768-1782.
3. Singhal S., Powles R., Treleaven J., Horton C., Swansbury G.J., Mehta J. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women. Bone Marrow Transplant 1996, 18:1049-1055.
4. Samuels B.L., Bitran J.D. High-dose intravenous melphalan: a review. J Clin Oncol 1995, 13:1786-1799.
5. Vistica D.T. Cytotoxicity as an indicator for transport mechanism: evidence that melphalan is transported by two leucine-preferring carrier systems in the L1210 murine leukemia cell. Biochim Biophys Acta 1979, 550:309-317.
6. Gera S., Musch E., Osterheld H.K., Loos U. Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma. Cancer Chemother Pharmacol 1989, 23:76-80.
7. Ardiet C., Tranchand B., Biron P., Rebattu P., Philip T. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases. Cancer Chemother Pharmacol 1986, 16:300-305.
8. Gouyette A., Hartmann O., Pico J.L. Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 1986, 16:184-189.
9. Reece P.A., Hill H.S., Green R.M., et al. Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother Pharmacol 1988, 22:348-352.
10. Tattersall M.H., Jarman M., Newlands E.S., Holyhead L., Milstead R.A., Weinberg A. Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer 1978, 14:507-513.
11. Bosanquet A.G., Gilby E.D. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 1982, 18:355-362.
12. Poplin E., Smith H., Behrens B., et al. SWOG 8825: melphalan GM-CSF: a phase I study. Gynecol Oncol 1992, 44:66-70.
13. Nath C.E., Shaw P.J., Trotman J., et al. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br J Clin Pharmacol 2010, 69:484-497.
14. Cornwell G.G., Pajak T.F., McIntyre O.R., Kochwa S., Dosik H. Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience. Cancer Treat Rep 1982, 66:475-481.
15. Giralt S. Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years?. Hematology Am Soc Hematol Educ Program 2005, 384-389.
16. Moreau P., Fiere D., Bezwoda W.R., et al. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. J Clin Oncol 1997, 15:660-666.
17. Lazarus H.M., Herzig R.H., Graham-Pole J., et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1983, 1:359-367.
18. Lilleby K., Garcia P., Gooley T., et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006, 37:1031-1035.
19. Phillips G.L., Meisenberg B., Reece D.E., et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant 2004, 10:473-483.
20. Hersh M.R., Ludden T.M., Kuhn J.G., Knight W.A. Pharmacokinetics of high dose melphalan. Invest New Drugs 1983, 1:331-334.
21. Selby P.J., McElwain T.J., Nandi A.C., et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987, 66:55-62.
22. Pritchard J., McElwain T.J., Graham-Pole J. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer 1982, 45:86-94.
23. Westerfield B.T., Michalski J.P., McCombs C., Light R.W. Reversible melphalan-induced lung damage. Am J Med 1980, 68:767-771.
24. Olivieri A., Corvatta L., Montanari M., et al. Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant 1998, 21:1049-1053.
25. Sirohi B., Cunningham D., Powles R., et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008, 19:1312-1319.
26. Harrison C.N., Gregory W., Hudson G.V., et al. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Br J Cancer 1999, 81:476-483.
27. Rajkumar S.V. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011, 8:479-491.
28. Blokhin N., Larionov L., Perevodchikova N., Chebotareva L., Merkulova N. Ann N Y Acad Sci 1958, 68:1128-1132. [Article in Russian].
29. McElwain T.J., Powles R.L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983, 2:822-824.
30. Barlogie B., Hall R., Zander A., Dicke K., Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986, 67:1298-1301.
31. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996, 335:91-97.
32. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
33. Fermand J.P., Ravaud P., Chevret S., et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998, 92:3131-3136.
34. Bladé J., Rosiñol L., Sureda A., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005, 106:3755-3759.
35. Fermand J.P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005, 23:9227-9233.
36. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006, 24:929-936.
37. Giralt S. Stem cell transplantation for multiple myeloma: current and future status. Hematology 2011, 2011:191-196.
38. Barlogie B., Jagannath S., Vesole D.H., et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997, 89:789-793.
39. Cavo M., Tosi P., Zamagni E., et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007, 25:2434-2441.
40. Kumar A., Kharfan-Dabaja M.A., Glasmacher A., Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009, 101:100-106.
41. Jagannath S., Vesole D.H., Glenn L., Crowley J., Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992, 80:1666-1672.
42. Moreau P., Milpied N., Mahé B., et al. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999, 23:1003-1006.
43. Moreau P., Facon T., Attal M., et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002, 99:731-735.
44. Palumbo A., Bringhen S., Bruno B., et al. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 2010, 115:1873-1879.
45. Facon T., Mary J.Y., Hulin C., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370:1209-1218.
46. Kumar S.K., Dingli D., Lacy M.Q., et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol 2008, 83:614-617.
47. Badros A., Barlogie B., Siegel E., et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001, 114:600-607.
48. Bashir Q., Shah N., Parmar S., et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. Leuk Lymphoma 2012, 53:118-122.
49. Tricot G., Alberts D.S., Johnson C., et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996, 2:947-952.
50. Badros A., Barlogie B., Siegel E., et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001, 114:822-829.
51. Raab M.S., Breitkreutz I., Hundemer M., et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica 2006, 91:1555-1558.
52. Parikh G.C., Amjad A.I., Saliba R.M., et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009, 15:812-816.
53. Shaw P.J., Nath C.E., Nivison-Smith I., et al. Higher melphalan exposure is associated with improved overall survival for myeloma patients undergoing autologous transplant. Biol Blood Marrow Transplant 2012, 18:S207.
54. Moreau P., Attal M., Pégourié B., et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 2011, 117:3041-3044.
55. van de Velde H.J., Liu X., Chen G., Cakana A., Deraedt W., Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007, 92:1399-1406.
56. Harousseau J.L., Attal M., Avet-Loiseau H., et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010, 28:4621-4629.
57. Lokhorst H.M., Schmidt-Wolf I., Sonneveld P., et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008, 93:124-127.
58. Cavo M., Tacchetti P., Patriarca F., et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010, 376:2075-2085.
59. Rosiñol L., Oriol A., Teruel A.I., et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012, 120:1589-1596.
60. Fenk R., Schneider P., Kropff M., et al. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol 2005, 130:588-594.
61. Qazilbash M.H., Saliba R.M., Nieto Y., et al. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 2008, 14:1401-1407.
62. Lahuerta J.J., Mateos M.V., Martínez-López J., et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica 2010, 95:1913-1920.
63. Roussel M., Moreau P., Huynh A., et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010, 115:32-37.
64. Harousseau J.L., Mathiot C., Attal M., et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial. 2008 ASCO Annual Meeting. J Clin Oncol 2008, 26(May 20 suppl). abstract 8505.
65. Sharma M., Khan H., Thall P.F., et al. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 2012, 118:2507-2515.
66. Tricot G., Vesole D.H., Jagannath S., Hilton J., Munshi N., Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996, 87:1196-1198.
67. Durie BG. Allogeneic bone marrow transplants for multiple myeloma: an IBMTR analysis (meeting abstract). 1995 ASCO Annual Meeting: abstract 1358.
68. Gahrton G., Tura S., Ljungman P., et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995, 13:1312-1322.
69. Crawley C., Iacobelli S., Björkstrand B., Apperley J.F., Niederwieser D., Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007, 109:3588-3594.
70. Giralt S., Aleman A., Anagnostopoulos A., et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002, 30:367-373.
71. Kröger N., Schwerdtfeger R., Kiehl M., et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002, 100:755-760.
72. Rotta M., Storer B.E., Sahebi F., et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009, 113:3383-3391.
73. Bruno B., Rotta M., Patriarca F., et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009, 113:3375-3382.
74. Lee C.K., Badros A., Barlogie B., et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003, 31:73-80.
75. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474-3480.
76. Rosiñol L., Pérez-Simón J.A., Sureda A., et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008, 112:3591-3593.
77. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007, 356:1110-1120.
78. Lokhorst H.M., van der Holt B., Cornelissen J.J., et al. Donor versus no-donor analysis of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012, 119:6219-6225. quiz 6399.
79. Gahrton G, Bjorkstrand B, Iacobelli S, et al. Tandem autologous (ASCT)/allogeneic reduced intensity conditioning transplantation (RIC) with identical sibling donor versus ASCT in previously untreated multiple myeloma (MM): long term follow up of a prospective controlled trial by the EBMT. 52st ASH Annual Meeting and Exposition. 2009: abstract 52.
80. Björkstrand B., Iacobelli S., Hegenbart U., et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011, 29:3016-3022.
81. Krishnan A, Pasquini MC, Ewell M, et al. Tandem autologous hematopoietic stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by HLA matched sibling non- myeloablative allogeneic HCT (auto-allo) for patients with standard risk (SR) multiple myeloma (MM): results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. 53rd ASH Annual Meeting and Exposition. December 2010: abstract 41.
82. Knop S, Liebisch P, Hebart H, et al. Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma: an interim analysis of the German DSMM V trial. 52nd ASH Annual Meeting and Exposition. 2009: abstract 51.
83. Moreau P., Garban F., Attal M., et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008, 112:3914-3915.
84. Krishnan A., Pasquini M.C., Logan B., et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011, 12:1195-1203.
85. Lokhorst H.M., van der Holt B., Cornelissen J.J., et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012, 119:6219-6225. quiz 6399.
86. Knop S, Liebisch P, Hebart H, et al. Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma - an interim analysis of the German DSMM V Trial. 52st ASH Annual Meeting and Exposition. 2009: abstract 51.
87. Skinner M., Sanchorawala V., Seldin D.C., et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004, 140:85-93.
88. Cibeira M.T., Sanchorawala V., Seldin D.C., et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011, 118:4346-4352.
89. Cohen A.D., Zhou P., Chou J., et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 2007, 139:224-233.
90. Gertz M.A. I don't know how to treat amyloidosis. Blood 2010, 116:507-508.
91. Lebovic D., Hoffman J., Levine B.M., et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008, 143:369-373.
92. Dietrich S., Schönland S.O., Benner A., et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010, 116:522-528.
93. Wechalekar A.D., Hawkins P.N., Gillmore J.D. Perspectives in treatment of AL amyloidosis. Br J Haematol 2008, 140:365-377.
94. Dispenzieri A., Lacy M.Q., Kyle R.A., et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001, 19:3350-3356.
95. Dispenzieri A., Kyle R.A., Lacy M.Q., et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004, 103:3960-3963.
96. Jaccard A., Moreau P., Leblond V., et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007, 357:1083-1093.
97. Kumar S., Dispenzieri A., Gertz M.A. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2008, 358:91. author reply 92-93.
98. Sanchorawala V., Wright D.G., Quillen K., et al. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant 2007, 40:557-562.
99. Helenglass G., Powles R.L., McElwain T.J., et al. Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission. Bone Marrow Transplant 1988, 3:21-29.
100. Michel G., Maraninchi D., Demeocq F., et al. Repeated courses of high dose melphalan and unpurged autologous bone marrow transplantation in children with acute non-lymphoblastic leukemia in first complete remission. Bone Marrow Transplant 1988, 3:105-111.
101. Maraninchi D., Pico J.L., Hartmann O., et al. High-dose melphalan with or without marrow transplantation: a study of dose-effect in patients with refractory and/or relapsed acute leukemias. Cancer Treat Rep 1986, 70:445-448.
102. Giralt S., Cohen A., Mehra R., et al. Preliminary results of fludarabine/melphalan or 2CDA/melphalan (2CDA/M) as preparative regimens for allogeneic progenitor cell transplantation (allo-PCT) in poor candidates for conventional myeloablative conditioning. Blood 1997, 90. 1853-1853.
103. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001, 97:631-637.
104. Terenzi A., Aristei C., Aversa F., et al. Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results. Transplant Proc 1996, 28:3101.
105. Gandhi V., Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002, 41:93-103.
106. Oran B., Giralt S., Saliba R., et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2007, 13:454-462.
107. van Besien K., Artz A., Smith S., et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005, 23:5728-5738.
108. van Besien K., Kunavakkam R., Rondon G., et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 2009, 15:610-617.
109. Mesa R.A., Silverstein M.N., Jacobsen S.J., Wollan P.C., Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1976-1995. Am J Hematol 1999, 61:10-15.
110. Devine S.M., Hoffman R., Verma A., et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002, 99:2255-2258.
111. Rondelli D., Barosi G., Bacigalupo A., et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005, 105:4115-4119.
112. Snyder D.S., Palmer J., Stein A.S., et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant 2006, 12:1161-1168.
113. Ciurea S.O., de Lima M., Giralt S., et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant 2010, 16:555-559.
114. Bonate P.L., Arthaud L., Cantrell W.R., Stephenson K., Secrist J.A., Weitman S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006, 5:855-863.
115. Long-Boyle J., Huang J., Rydholm N., et al. Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation. J Clin Pharmacol 2011, 51:679-686.
116. van Besien K., Stock W., Rich E., et al. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:913-921.
117. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
118. Philip T., Biron P., Philip I., et al. Massive therapy and autologous bone marrow transplantation in pediatric and young adults Burkitt's lymphoma (30 courses on 28 patients: a 5-year experience). Eur J Cancer Clin Oncol 1986, 22:1015-1027.
119. Anderson C.C., Goldstone A.H., Souhami R.L., et al. Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma. Cancer Chemother Pharmacol 1986, 16:170-175.
120. Mills W., Chopra R., McMillan A., Pearce R., Linch D.C., Goldstone A.H. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995, 13:588-595.
121. Gaspard M.H., Maraninchi D., Stoppa A.M., et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol 1988, 22:256-262.
122. Caballero M.D., Rubio V., Rifon J., et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997, 20:451-458.
123. Liu H.W., Seftel M.D., Rubinger M., et al. Total body irradiation compared with BEAM: long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2010, 78:513-520.
124. Kim J.E., Lee D.H., Yoo C., et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res 2011, 35:183-187.
125. Argiris A., Seropian S., Cooper D.L. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Ann Oncol 2000, 11:665-672.
126. Deconinck E., Lamy T., Foussard C., et al. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 2000, 109:736-742.
127. Kyriakou C., Canals C., Goldstone A., et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008, 26:218-224.
128. Nachbaur D., Greinix H.T., Koller E., et al. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR). Ann Hematol 2005, 84:462-473.
129. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002, 359:2065-2071.
130. Musso M., Scalone R., Marcacci G., et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant 2010, 45:1147-1153.
131. Visani G., Malerba L., Stefani P.M., et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011, 118:3419-3425.
132. Srivastava A., Bradstock K.F., Szer J., de Bortoli L., Gottlieb D.J. Busulfan and melphalan prior to autologous bone marrow transplantation. Bone Marrow Transplant 1993, 12:323-329.
133. Kebriaei P., Madden T., Kazerooni R., et al. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant 2011, 17:412-420.
134. Nieto Y, Anderlini P, Popat U, et al. Gemcitabine, busulfan and melphalan (GemBuMel) is a new high-dose chemotherapy (HDC) regimen with high activity in refractory Hodgkin's lymphoma (HL) patients receiving an autologous stem-cell transplant (ASCT): a contemporaneous comparison with BEAM and busulfan/melphalan (BuMel). 53rd ASH Annual Meeting and Exposition. 2010:abstract 690.
135. Przepiorka D., van Besien K., Khouri I., et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 1999, 10:527-532.
136. Cull G.M., Haynes A.P., Byrne J.L., et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol 2000, 108:754-760.
137. Faulkner R.D., Craddock C., Byrne J.L., et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004, 103:428-434.
138. Anderlini P., Giralt S., Andersson B., et al. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 2000, 26:615-620.
139. Branson K., Chopra R., Kottaridis P.D., et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002, 20:4022-4031.
140. Delgado J., Thomson K., Russell N., et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 2006, 107:1724-1730.
141. Anderlini P., Saliba R., Acholonu S., et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008, 93:257-264.
142. Deconinck E., Cahn J.Y., Milpied N., et al. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan). Bone Marrow Transplant 1997, 20:731-735.
143. Sebban C., Lepage E., Vernant J.P., et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994, 12:2580-2587.
144. Zander A.R., Keating M., Dicke K., et al. A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission. J Clin Oncol 1988, 6:1548-1557.
145. Cho B.S., Lee S., Kim Y.J., et al. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia 2009, 23:1763-1770.
146. Yuji K., Miyakoshi S., Kato D., et al. Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma. Biol Blood Marrow Transplant 2005, 11:314-318.
147. Cutler C., Stevenson K., Kim H.T., et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant 2011, 46:659-667.
148. Waki F., Masuoka K., Fukuda T., et al. Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients. Biol Blood Marrow Transplant 2011, 17:841-851.
149. Lacerda J.F., Martins C., Carmo J.A., et al. Haploidentical stem cell transplantation with purified CD34 cells after a chemotherapy-alone conditioning regimen. Biol Blood Marrow Transplant 2003, 9:633-642.
150. Bethge W.A., Faul C., Bornhäuser M., et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis 2008, 40:13-19.
151. Ciurea S.O., Mulanovich V., Jiang Y., et al. Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:1169-1175.
152. Ciurea S.O., Saliba R., Rondon G., et al. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 2010, 45:429-436.
153. Ciurea SO, Saliba RM, Bayraktar UD, et al. Improved early outcomes with T-cell replete (TCR) compared with T-cell depleted (TCD) haploidentical stem cell transplantation (HaploSCT). 53rd ASH Annual Meeting and Exposition. 2011: abstract 320.
154. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
155. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:865-872.
156. Malladi R.K., Peniket A.J., Norton A.E., et al. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies. Eur J Haematol 2004, 73:85-92.
157. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005, 23:9387-9393.
158. Nakamura R., Rodriguez R., Palmer J., et al. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. Bone Marrow Transplant 2007, 40:843-850.
159. Small T.N., Young J.W., Castro-Malaspina H., et al. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant 2007, 13:235-244.
160. de Lima M., Champlin R.E., Thall P.F., et al. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 2008, 22:258-264.
161. Marks R., Potthoff K., Hahn J., et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood 2008, 112:415-425.
162. Kirschbaum M.H., Stein A.S., Popplewell L., et al. A phase i study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation. Biol Blood Marrow Transplant 2012, 18:432-440.
163. Morris E., Thomson K., Craddock C., et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004, 104:3865-3871.
164. Rodriguez R., Nademanee A., Ruel N., et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006, 12:1326-1334.
165. Thomson K.J., Morris E.C., Bloor A., et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:426-432.
166. Alvarez I., Sureda A., Caballero M.D., et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006, 12:172-183.
167. Peggs K.S., Sureda A., Qian W., et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007, 139:70-80.